GLOBALRPH ADVANCED VANCOMYCIN CALCULATOR CLINICAL REVIEW AND IMPLEMENTATION LIMITATIONS Release: 1.8 (generated infusion schedule selection updated) Evidence review date: 2026-10-17 PURPOSE This review accompanies the retained five-prior Advanced Vancomycin Calculator. Version 1.8 adds output zero trimming, an explicit generated-infusion schedule choice, average steady-state concentration, and linked equation background. The established PK equations and model parameters remain unchanged. The raw entry preservation and field validation introduced in v1.7 remain active. The supplied dose-based schedule differs from the reviewed Hospira label's minimum 60-minute duration and maximum 10 mg/min rate. The latter remains the initial default and a separate administration review. Dose bands do not alter actual administration history or an explicitly entered custom infusion. The above-2000-mg band requires a choice of 2.5 or 3 hours, initially 3 hours. See globalrph-vanco-equations.html for the exact bands, applicable equations, primary links, and differences from the legacy references supplied for review. Version 1.6 corrects candidate range ranking and CRRT interval preference, infusion defaults and administration review, obesity loading-reference precedence, optimizer search, conventional numerical stability, and report reproducibility. Specified unreliable fits retain diagnostics but withhold proposed regimens. The update does not add a population model or establish external clinical validation. Detailed findings are in audit/CLINICAL_AUDIT.md. The clinician guide is globalrph-vanco-advanced-help.html. EVIDENCE BASIS The IDSA listing still identifies the 2020 joint ASHP/IDSA/PIDS/SIDP monitoring guideline as current. No superseding US joint vancomycin monitoring guideline was identified in the search completed on the review date. The clinical target and MIC interpretation are summarized in the guide's Scope section [1]. The DoseMeRx webinar is a workflow source for education, handoff, monitoring communication, competency review, and downtime planning [8]. Local practices described by speakers are not hard-coded universal dosing or monitoring rules. No equation or population eligibility was changed on webinar authority. The 2026 study cited in the supplied review was independently located [7]. Its observational design concerns specific model changes in a commercial platform. It supports evaluating model dependence and input quality, not substituting new priors into this implementation. The timing exclusions in that study are not a universal definition of postdistributional sampling. RETAINED WORKFLOWS - Pre-dose/empiric estimate. - Assessment of a current regular regimen without measured concentrations. - One concentration at or near steady state. - Two concentrations at or near steady state. - Two concentrations after the first dose. - Conventional, Bayesian, and eligible conventional-fallback pathways. - Mathematical exact-target and clinician-selected regimen evaluation. The conventional single-level option fixes Vd and solves for elimination. Its dependence on Vd is explicitly described. It is not presented as the guideline two-concentration equation method. The first-dose conventional calculation retains its older one-compartment approach, not the alpha-distribution-phase compensation described in the 2023 study [9]. MODEL AND RENAL-COVARIATE REVIEW Goti [2]: The retained non-dialysis implementation uses selected-weight Cockcroft-Gault with its existing limits. Source-study inclusion of HD does not make this tool suitable for HD. Original-versus-modified preprocessing in other platforms must not be assumed equivalent to the retained implementation. The original abstract was accessible; the full coefficient/residual table, original preprocessing, and body of the 2019 erratum [12] were not obtained. Detailed original-source transcription verification remains incomplete. Roberts [3]: The source involved critically ill adults, not a population limited to non-obese adults. Manual use is permitted for an eligible obese ICU case; automatic selection prioritizes Zhang at BMI at least 30. The source renal covariate was measured, BSA-indexed 24-hour urinary CrCl. The calculator substitutes indexed Cockcroft-Gault and applies a model derived under continuous infusion to intermittent infusion. The guide explicitly identifies both approximations. A small numerical uncertainty interval cannot remove uncertainty introduced by a covariate proxy. Full primary equations and Table 2 confirm structural coefficients and reported CV/SD inputs. The source writes an exponential-plus-additive residual equation; the code uses a normal additive-plus-proportional residual variance approximation. Exact original stochastic-model reproduction has not been established. Zhang [4]: The retained renal input is indexed CKD-EPI 2009 without a race coefficient. Weight and ICU status separately affect model clearance. This is not an unindexed mL/min Cockcroft-Gault input. Renal replacement was outside the source population. The source discussion's proportional MIC escalation is not adopted in place of the consensus exposure guardrail. Full Table 2 confirms structural coefficients and IIV/residual variances. The 90-kg weight center in that table differs from the narrative's 100-kg description. The supplementary renal table omits the standard female CKD-EPI multiplier 1.018; the code includes it. The original Levey equation [13] supports the standard factor, but exact investigator covariate generation remains unresolved. Tsai CRRT [5]: The retained pathway uses body weight and CRRT status. It does not numerically incorporate effluent intensity, urine output, modality, downtime, or time-varying support. The source paper's time-varying model does not confer those capabilities on a fixed-status implementation. Central volume remains fixed in both one- and two-level fits. Interrupted or changed CRRT is outside the retained calculation rather than represented by an invented correction factor. The retained Q is explicitly the no-temporary-mechanical-circulatory-support branch. Temporary extracorporeal VAD as well as ECMO remains unsupported. Table 2 confirms this structural branch and the CL variance; Q/Vp variability is not fitted. Treating additive 1.39 as SD is consistent with official Phoenix NLME documentation [14], but the original author model file was not obtained. Belabbas [6]: The retained hematologic-malignancy implementation uses actual-weight Cockcroft-Gault with AML/neutropenia covariates. Applicability should not be extended to every solid tumor or unspecified cancer diagnosis. The original abstract confirms structure, named covariates, and typical CL/Vd. The full numerical table was not obtained. Detailed exponent, neutropenia multipliers, IIV/residual values, and original preprocessing therefore remain incompletely verified against primary full text. Conventional manual CrCl and amputation options remain conventional options. They do not silently replace the separate covariates used by Bayesian models. The result displays calculated and used values, units, weight basis, limits, override status, and reasons for differences. Retained implementation limits are not represented as universal clinical limits. INPUT HISTORY AND SAMPLING The clinical form reconstructs identical, regularly spaced recorded doses from dose, interval, actual infusion duration, and dose count. Sample times are elapsed hours from the latest infusion start. The first-dose workflow uses one dose and does not account for unrecorded residual vancomycin from prior therapy. An unequal loading dose, held dose, incomplete infusion, irregular interval, additional administration, or missing earlier exposure can make that history inaccurate. Known inconsistent history, renal change, or CRRT changes must not be disguised as a regular regimen or allowed through conventional fallback. Known sample contamination, collection during infusion, duplicate levels, and implausible timing are relevant data-quality findings. A 15-minute spacing screen is a conservative software check. It is not an evidence-based claim that 16 minutes always provides adequate information. Pharmacokinetic distribution and clinical sample selection remain separate considerations. Conventional workflows now warn when a permitted sample is during infusion or less than one hour after infusion completion. This is a caution about the first-order assumption, not a universal one-hour hard sampling cutoff. GUIDANCE AND MIC BEHAVIOR MIC alters the descriptive AUC/MIC ratio, not the selected exposure target. The upper target boundary is an exposure-review trigger, not a binary toxicity threshold. Target AUC is displayed separately from AUC/MIC and their units. Monitoring is reassessed after meaningful clinical, renal, CRRT, or regimen changes and unexpected concentrations. No automatic every-three-or-five-day schedule is prescribed. Fixed-parameter calculations are not made appropriate for unstable physiology by switching from one to two compartments. REGIMEN RANKING, INFUSION, AND LOADING REFERENCES Generated options within AUC24 400-600 mg*h/L rank ahead of outside-range options. Target proximity and practical schedule preferences then apply. The CRRT pathway preserves its explicit 12/24-hour interval preference. The candidate grid and score are software heuristics, not validated prescribing rules. AUC at the target does not establish infusion suitability. All generated conventional and Bayesian regimens use at least 60 minutes and no faster than 10 mg/min, rounded upward to the next 15 minutes. This is the conservative default from the reviewed Hospira IV powder label [11]. The calculator has no product selector and does not assert that all product labels are identical. For 1000 mg, the generated duration is 1.75 h. Proposed custom regimens show mg/min, the default minimum, and a warning when shorter. Historical infusion duration is retained exactly for fitting; do not rewrite actual administration history to match a proposed default. The loading reference uses actual weight, rounding to 250 mg, and a 3000-mg cap. Obesity and CRRT use 20-25 mg/kg; the wider 20-35 mg/kg critical-illness reference applies to patients without obesity. This reference remains separate from fitted maintenance dosing and requires indication and local-protocol review. CONVENTIONAL NUMERICAL STABILITY AND REVIEW LIMITS The represented equations are unchanged. Logarithmic concentration ratios and finite-infusion amplitudes now use stable log1p/expm1 forms. The log-down AUC segment is evaluated as its exponential integral, so an underflowed terminal concentration does not produce a NaN trapezoid. Exact first-dose AUC0-24 uses a cancellation-resistant sum of infusion and postinfusion areas. For measured conventional fits, CL must be strictly between 0.03 and 40 L/h and Vd strictly between 2 and 800 L to make proposed regimen recommendations available. These reuse software PK operating limits; they are not validated physiologic cutoffs. No added kel-based gate was introduced. Derived parameters are not clamped. A finite out-of-envelope result remains diagnostic only, while nonfinite equation output becomes a conventional-fit failure. UNCERTAINTY: WHAT IS AND IS NOT SHOWN The information label separates prior-only, one-level, and two-level estimates. No measured concentration means there is no fitted posterior. Population-prior spread, when available, is separately labeled. With one level, CL is fitted and central volume is held at its prior. With two, CL and central volume are fitted except for Tsai. Other structural parameters remain fixed. This makes the local range conditional on more than the observed sample values alone. The omegaCl/omegaVc fields are log-parameter variances, not standard deviations. CV inputs use ln(1 + CV^2). The normal concentration residual variance is additiveSd^2 + (proportionalSd * prediction)^2. Full numerical and source-status matrices are in ADVANCED_METHODS.md and audit/CLINICAL_AUDIT.md. Version 1.6 searches three starting points for a CL-only fit and nine for a CL/Vc fit. No optimizer runs without measured concentrations. The best valid objective found is selected with deterministic near-tie handling; the grid does not prove a global optimum. Converged fits more than 0.1 apart on the log scale and within 2 negative-log-posterior units are reported as competing fits. Those thresholds are numerical ambiguity screens, not clinical thresholds or probability intervals. Alternative CL/Vc and score gaps are shown; local ranges are withheld when such fits exist. A valid selected point is not automatically withheld solely because a competing minimum exists. The local approximation uses log-scale curvature around the fitted parameters and a multiplier of 1.96. It is described as an approximate model-based range, not as a calibrated patient-level 95% confidence/credible interval. Invalid curvature, unreliable boundary fits, failed convergence, or range endpoints crossing eta or software PK limits can make it unavailable. Competing fits also make a single local range unsuitable. Such ranges are withheld rather than silently clipped. Unavailable must not be interpreted as zero uncertainty. For fixed daily dose D and constant CL at linear steady state: AUCss24 = D / CL AUC lower = D / CL upper AUC upper = D / CL lower These are arithmetic transformations, not separately validated clinical coverage probabilities. The range does not include model disagreement, future physiology, missing doses, or all structural/residual uncertainty. It must not be computed by retargeting D for every CL value, which would conceal variation. AUCss24 is not automatically actual first-day or next-24-hour exposure. A single first-dose AUC0-infinity equals dose/CL and is distinct from AUC0-24. The report must keep these labels distinct. MODEL SENSITIVITY The comparison evaluates the same fixed regimen with each eligible model using the same patient observations. It lists ineligible/failed models and their reasons. It does not auto-select the most favorable AUC or replace the clinician's prior selection. Comparing separately retargeted doses would hide disagreement. Any discrepancy alert is a review aid, not a new validated decision threshold. REPORT AND PRIVACY The report contains only the fields and computed values represented by the form, including original/normalized units and elapsed event times. Infusion starts and stops are reconstructed elapsed values, not verified clinical clock timestamps. Absolute clinical dates were not entered. Synthetic calendar dates used internally by timing code must never be exported as patient-event dates. Report creation time, if present, is explicitly a report timestamp. The evaluated patient, method, workflow, target/MIC, flags, regimen, and samples are displayed in a read-only calculation snapshot. The calculation timestamp and report-generation timestamp are distinct from administration or sample times. Both custom buttons evaluate the displayed custom fields using that snapshot; the download action first recalculates them. Invalid custom entries prevent download. Changed clinical fields require the main calculation to be rerun. Withheld proposed regimen values are omitted; entered-history diagnostics, competing-fit diagnostics, units, and range status remain explicitly labeled. The form requests no patient name, MRN, or birth date. The application does not save entered clinical inputs. PHP handles form POST values server-side; the JavaScript edition computes in the browser. A downloaded report persists only where the user elects to save the downloaded copy. This description concerns the application; it does not certify independent hosting or browser retention. POOR-FIT WORKFLOW Review actual administrations and sample times; reconcile delays/omissions and incomplete doses; investigate infusion-line or during-infusion samples; review renal trajectory, fluid status, and CRRT changes; obtain another informative concentration when appropriate; reassess eligible models and institutional alternatives. Conventional two-level estimation is appropriate only when its own stable-physiology and timing assumptions are met. Proposed primary, exact-target, custom, and candidate regimens are withheld when a measured Bayesian fit does not converge, reaches a parameter boundary, has an invalid objective, or fits a concentration with nonfinite or absolute standardized residual greater than 3. Fitted PK and entered-regimen exposure remain diagnostic only. Unavailability of a local Hessian range alone is not the same as this recommendation guard. VALIDATION BOUNDARY The authoritative final execution counts and package checks are maintained in tests/RELEASE_INTEGRITY.txt and RELEASE_REVIEW.html. See tests/README.md for the numerical methods. Clinical presentation checks and primary-source review are recorded in audit/clinical-review/ and audit/CLINICAL_AUDIT.md. Three full primary model papers were checked, with the qualifications above. Two detailed primary tables and a relevant erratum body remain unavailable. No original author control streams or complete variance-covariance matrices were independently executed. No external patient cohort or calibrated coverage study of this exact implementation was completed. Numerical identities, golden cases, independent arithmetic, repeated workload, and agreement across PHP/JavaScript can detect implementation faults and show reproducibility. They do not establish patient-level calibration, population transportability, prospective outcomes, or equivalence to another dosing platform. Remaining clinical evidence work cannot be replaced by another version number. REFERENCES [1] Rybak MJ et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review. Am J Health-Syst Pharm. 2020;77:835-864. DOI: 10.1093/ajhp/zxaa036. PMID: 32191793. https://doi.org/10.1093/ajhp/zxaa036 https://www.idsociety.org/practice-guideline/vancomycin/ [2] Goti V et al. Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a population pharmacokinetic model-based analysis. Ther Drug Monit. 2018;40:212-221. DOI: 10.1097/FTD.0000000000000490. PMID: 29470227. https://doi.org/10.1097/FTD.0000000000000490 https://pubmed.ncbi.nlm.nih.gov/29470227/ [3] Roberts JA et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011;55:2704-2709. DOI: 10.1128/AAC.01708-10. PMID: 21402850. https://doi.org/10.1128/AAC.01708-10 https://pubmed.ncbi.nlm.nih.gov/21402850/ [4] Zhang T et al. How to dose vancomycin in overweight and obese patients with varying renal (dys)function in the novel era of AUC 400-600 mg*h/L-targeted dosing. Clin Pharmacokinet. Published online 2023. DOI: 10.1007/s40262-023-01324-5. PMID: 37971650. https://doi.org/10.1007/s40262-023-01324-5 https://link.springer.com/article/10.1007/s40262-023-01324-5 [5] Tsai MT et al. Population pharmacokinetics of vancomycin in intensive care patients with the time-varying status of temporary mechanical circulatory support or continuous renal replacement therapy. Infect Dis Ther. 2024. DOI: 10.1007/s40121-024-01071-5. PMID: 39541003. https://doi.org/10.1007/s40121-024-01071-5 https://link.springer.com/article/10.1007/s40121-024-01071-5 [6] Belabbas T et al. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. J Infect Chemother. 2023;29:391-400. DOI: 10.1016/j.jiac.2023.01.010. PMID: 36682608. https://doi.org/10.1016/j.jiac.2023.01.010 https://pubmed.ncbi.nlm.nih.gov/36682608/ [7] Tong DMH, Brooks JT, Keizer RJ, Hughes JH. Vancomycin target attainment improved following population pharmacokinetic model switch: a large-scale quasi-experimental study of precision dosing. JAC Antimicrob Resist. 2026;8:dlag016. DOI: 10.1093/jacamr/dlag016. PMID: 41710913. https://doi.org/10.1093/jacamr/dlag016 https://academic.oup.com/jacamr/article/8/1/dlag016/8488539 [8] DoseMeRx. Do's and Don'ts of Bayesian Dosing: Webinar Recording. Accessed 2026-10-16. Workflow source; no DOI. https://doseme-rx.com/vancomycin/articles/dos-and-donts-bayesian-dosing [9] Sujjavorakul K et al. Predicting the area under the plasma concentration-time curve (AUC) for first dose vancomycin using first-order pharmacokinetic equations. Antibiotics. 2023;12:630. DOI: 10.3390/antibiotics12040630. PMID: 37106993. https://doi.org/10.3390/antibiotics12040630 https://pubmed.ncbi.nlm.nih.gov/37106993/ [10] Olney KB et al. Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy. 2022;42:284-291. DOI: 10.1002/phar.2670. PMID: 35134264. https://doi.org/10.1002/phar.2670 https://pubmed.ncbi.nlm.nih.gov/35134264/ [11] Hospira. Vancomycin hydrochloride powder for solution, IV. DailyMed prescribing information updated April 1, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9ea31ec-4c26-452f-b07b-c5f894212cd5 Product-specific conservative infusion source; the calculator has no product selector. Historical durations remain as administered. [12] Goti paper erratum. Ther Drug Monit. 2019;41(4):549. DOI: 10.1097/FTD.0000000000000666. PMID: 31306395. https://pubmed.ncbi.nlm.nih.gov/31306395/ Existence verified; erratum body not obtained. [13] Levey AS et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. PMID: 19414839. https://pubmed.ncbi.nlm.nih.gov/19414839/ https://pmc.ncbi.nlm.nih.gov/articles/PMC2763564/ The original equation includes the female 1.018 multiplier. Indexed primary equation text was available despite intermittent direct-rendering restrictions. [14] Certara. Phoenix 8.3 official model and residual-error documentation. https://onlinehelp.certara.com/phoenix/8.3/topics/nlmeuistructure.htm Supports the additive-error SD convention; not author model-file verification. [15] Alsultan A et al. External validation of obese/critically ill vancomycin population pharmacokinetic models in critically ill patients who are obese. J Clin Pharmacol. Published online 2023. DOI: 10.1002/jcph.2375. PMID: 37862131. https://pubmed.ncbi.nlm.nih.gov/37862131/ Original comparison supports model-dependent performance in the studied cohort; it does not validate the exact GlobalRPh implementation.